Last Price
0.073
Today's Change
-0.002 (2.66%)
Day's Change
0.07 - 0.08
Trading Volume
10,841,992
Market Cap
1 Million
Shares Outstanding
1 Billion
Avg Volume
63,964,555
Avg Price (50 Days)
0.06
Avg Price (200 Days)
0.12
PE Ratio
0.00
EPS
0.00
Earnings Announcement
28-May-2025
Previous Close
0.07
Open
0.08
Day's Range
0.07 - 0.08
Year Range
0.04 - 0.33
Trading Volume
10,841,992
1 Day Change
-3.07%
5 Day Change
-4.47%
1 Month Change
53.05%
3 Month Change
45.40%
6 Month Change
-56.73%
Ytd Change
45.40%
1 Year Change
-75.36%
3 Year Change
-94.90%
5 Year Change
-98.90%
10 Year Change
-97.23%
Max Change
-97.23%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.